Form 4: Amylyx Pharmaceuticals Director Karen Firestone Granted 25,000 Stock Options

Amylyx Pharmaceuticals Director Karen Firestone was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026 or the next annual meeting.

Summary

• Karen Firestone, a Director of Amylyx Pharmaceuticals, Inc. (AMLX), was granted 25,000 stock options.
• The options have an exercise price of $5.05 per share.
• The grant date for these options was June 5, 2025.
• The options will vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, contingent on her continuous service to the Issuer.
• The options are exercisable immediately upon vesting and expire on June 4, 2035.
• Following this transaction, Ms. Firestone beneficially owns 25,000 stock options directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, and it is a routine compensation practice.

Positives

• The grant of 25,000 stock options to Director Karen Firestone aligns her interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $5.05 provides a clear benchmark for future stock performance relative to the grant.

Negatives

• NA

Risks

• NA

Future Outlook

The stock options granted to Director Karen Firestone are set to vest in full by June 5, 2026, or the date of the next annual meeting, contingent on her continued service to the company.

Management Comments

• NA

Industry Context

This Form 4 filing reflects a standard practice of compensating directors with equity, common across the biotechnology and pharmaceutical industries, to align director interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common compensation practice in publicly traded companies, particularly within the biotechnology sector, aiming to align executive and director incentives with shareholder returns. While specific grant sizes vary, 25,000 options for a director is within typical ranges for companies of similar market capitalization to Amylyx Pharmaceuticals.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with shareholders by incentivizing long-term stock price appreciation.
• Employees: No direct impact mentioned for general employees.

Next Steps

• The stock options are scheduled to vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, subject to continuous service.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Form 4, stock options, insider transaction, director compensation, equity grant, beneficial ownership